LONDON, March 4, 2026 /PRNewswire/ — The “Structural Heart Devices Market – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032” report has been added to the Credence Research Inc. offering.The global Structural Heart Devices Market was valued at USD 5.21 billion in 2018, reached USD 6.68 billion in 2024, and is anticipated to reach USD 12.93 billion by 2032, registering a CAGR of 8.65% during the forecast period. The market’s growth reflects rising structural heart disease prevalence, expanding clinical indications for transcatheter therapies, and strong physician and patient preference for minimally invasive procedures that improve recovery outcomes.Key Takeaways:
Regional Growth Reflects Procedure Adoption and Healthcare Capacity
Credence Research Inc,
Tower C-1105, S 25,
Akash Tower,
Vishal Nagar,
Pimple Nilakh, Haveli,
Pune – 411027, India
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.credenceresearch.com/Logo – https://mma.prnewswire.com/media/2562161/Credence_Research_Logo.jpgSOURCE Credence Research Inc.
- Rising prevalence of valvular heart disease and congenital heart defects is increasing demand for advanced structural heart interventions across aging populations.
- Minimally invasive transcatheter procedures especially TAVR continue to accelerate adoption due to faster recovery, lower procedural risk, and broader eligibility across risk categories.
- Ongoing innovation in transcatheter heart valves, delivery systems, and closure devices, supported by integrated imaging and navigation technologies, is improving procedural precision and outcomes.
- North America leads with ~40.8% share in 2024, supported by advanced cardiac care infrastructure and higher procedure volumes, while Asia Pacific is the fastest-growing region with ~10.0% CAGR driven by expanding healthcare investment and access.
- By Product, the market includes Heart Valve Devices (Surgical Heart Valves, Transcatheter Heart Valves), Annuloplasty Rings, Occluders & Delivery Systems, and Other Products.
- By Procedure, the market includes Replacement Procedures (SAVR, TAVR, TMVR, Others) and Repair Procedures (LAAC, TMVr, TTVr, Valvuloplasty, Others).
- By End-use, the market includes Hospitals, Ambulatory Surgical Centers, Cardiac Catheterization Labs, and Other End Use.
- By Geography, the market is analyzed across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, with country-level coverage including the U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, China, Japan, India, South Korea, Southeast Asia, Brazil, Argentina, GCC countries, and South Africa.
- This report delivers a detailed view of a high-impact cardiovascular devices segment, with the market projected to nearly double by 2032, supported by strong transcatheter procedure momentum.
- It helps decision-makers evaluate how TAVR expansion, transcatheter mitral/tricuspid innovation, and closure device adoption are reshaping structural heart care pathways.
- The study provides regional insights across major markets and emerging economies, helping manufacturers and stakeholders prioritize investments, partnerships, and expansion strategies.
- For CXOs, investors, hospitals, and device innovators, this report offers actionable intelligence on competitive positioning, procedure trends, regulatory dynamics, and growth opportunities.
- Industry Landscape and Value Chain Assessment
- Supply-Side Evaluation
- Demand-Side Evaluation
- Stakeholder Mapping
- Porter’s Five Forces Review
- PESTLE Environment Assessment
- Market Forecast and Future Direction
- Short-Term Forecast (0–2 Years)
- Mid-Term Forecast (3–5 Years)
- Long-Term Forecast (5–10 Years)
- Market Entry and Expansion Strategy
- Customer and End-User Analysis
- Customer Experience Comparison
- Growth Opportunity Assessment
- Channel and Distribution Review
- Pricing Movement Analysis
- Regulatory and Compliance Review
- Sustainability and ESG Assessment
- Risk and Disruption Analysis
- Investment Return and Cost Evaluation
Attribute | Details |
Market Size 2018 | USD 5.21 Billion |
Market Size 2024 | USD 6.68 Billion (USD 6,683.01 Million) |
Market Size 2032 | USD 12.93 Billion (USD 12,931.90 Million) |
CAGR (2025–2032) | 8.65 % |
Forecast Period | 2025–2032 |
Base Year | 2024 |
Segmentation Covered | Product, Procedure, End-use, Geography |
Key Regions | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
Major Players | Abbott, Medtronic, Boston Scientific, Edwards Lifesciences, LivaNova, AtriCure, BIOMERICS, JenaValve, LEPU Medical, CryoLife, NUMED |
- North America holds the largest share of the structural heart devices market, accounting for approximately 40.8% of the global market in 2024. The regional market size reached USD 2.73 billion in 2024 (up from USD 2.15 billion in 2018) and is projected to reach USD 5.30 billion by 2032, expanding at a CAGR of 8.7%. Advanced hospital infrastructure, robust adoption of transcatheter therapies, and higher procedure volumes support regional dominance.
- Europe follows with approximately 24.6% share in 2024, rising from USD 1.33 billion in 2018 to USD 1.64 billion in 2024, and is projected to reach USD 2.97 billion by 2032 at a CAGR of 7.7%. Strong cardiac centers, supportive reimbursement structures, and rising valvular disease prevalence contribute to steady growth.
- Asia Pacific is the fastest-growing region with ~10.0% CAGR and approximately 21.9% share in 2024. The market expanded from USD 1.09 billion in 2018 to USD 1.47 billion in 2024 and is expected to reach USD 3.15 billion by 2032, driven by expanding access, growing healthcare investment, and increasing adoption of minimally invasive procedures in major countries including China, Japan, and India.
- Abbott;
- AtriCure;
- BIOMERICS;
- Boston Scientific;
- BRAILE;
- CryoLife;
- Edwards;
- JENAVALVE;
- LEPU MEDICAL;
- LivaNova;
- Medtronic;
- NUMED
- In July 2024, Edwards Lifesciences announced agreements to acquire JenaValve Technology (transcatheter treatment of aortic regurgitation) and to acquire Endotronix (heart-failure management solutions), positioning both as expansions of its structural heart portfolio.
- In August 2024, Edwards Lifesciences acquired JC Medical from Genesis MedTech, adding JC Medical’s transcatheter aortic valve replacement technology aimed at native aortic regurgitation, and also made an additional equity investment of $25 million.
Credence Research Inc,
Tower C-1105, S 25,
Akash Tower,
Vishal Nagar,
Pimple Nilakh, Haveli,
Pune – 411027, India
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.credenceresearch.com/Logo – https://mma.prnewswire.com/media/2562161/Credence_Research_Logo.jpgSOURCE Credence Research Inc.
Source link
Leave a Reply